Clarivate Plc filed its third-quarter 2026 earnings release on November 3, 2026, reporting results for the three and nine months ended September 30, 2026, including the completion of the Life Sciences & Healthcare segment divestiture and updated full-year financial outlook.

Key Highlights

  • Continuing-operations revenues: Total revenues from continuing operations were $481.6 million for Q3 2026, compared to $530.3 million in Q3 2025, a decrease of $48.7 million, or 9.2%, primarily due to inorganic disposals.
  • Net loss widened: Net loss including LS&H was $80.8 million, or $0.13 per diluted share, versus a net loss of $28.3 million, or $0.04 per diluted share, in Q3 2025, driven by a $62.2 million non-cash LS&H goodwill impairment charge.
  • Adjusted EBITDA: Adjusted EBITDA including discontinued operations was $245.3 million in Q3 2026, compared to $252.4 million in Q3 2025.
  • Organic ACV growth: Organic ACV for continuing operations grew 1.8% compared to September 30, 2025, according to the filing.
  • LS&H divestiture completed: On October 6, 2026, the company completed the sale of the LS&H segment for net cash proceeds of $488.4 million.
  • Debt reduction: Total debt outstanding was $4,176.1 million as of September 30, 2026, a decrease of $293.8 million compared to the prior year.
  • Full-year 2026 revenue outlook: The company updated its full-year 2026 revenue outlook to $1.965 billion to $1.985 billion, excluding discontinued operations.

Clarivate Third Quarter 2026: Revenue Trends, Divestiture Impact, and Updated Outlook

Clarivate Plc (NYSE:CLVT) reported third-quarter 2026 results showing declining total revenues alongside improving organic metrics, according to the filing. Total revenues including the LS&H segment were $567.9 million, down from $623.1 million in Q3 2025. Revenues from continuing operations were $481.6 million, compared to $530.3 million a year earlier. The company attributed the year-over-year decline primarily to inorganic disposals. Organic revenues for continuing operations increased 0.4%, with organic subscription growth of 1.5% and organic re-occurring growth of 0.7% partially offset by lower organic transactional revenues.

Subscription revenues for continuing operations rose $2.4 million, or 0.7%, to $338.3 million, while re-occurring revenues increased $0.5 million, or 0.5%, to $105.8 million. Transactional revenues decreased $51.6 million to $37.5 million, primarily due to product group wind-downs within the Academia & Government segment. Adjusted net income including LS&H was $136.0 million, or $0.21 per diluted share, compared to $119.3 million, or $0.18 per diluted share, in Q3 2025. For the first nine months of 2026, the company generated $399.0 million of operating cash flow and $233.1 million of free cash flow, including discontinued operations.

On the balance sheet, cash and cash equivalents stood at $257.0 million as of September 30, 2026, a decrease of $72.2 million from December 31, 2025. The company reported retiring $192.6 million aggregate principal of senior secured notes due 2028 and senior notes due 2029 through debt repurchases at an approximate 5% discount to par, in addition to a $100.0 million accelerated repayment in January 2026. The company updated its full-year 2026 outlook to reflect the completed LS&H divestiture, projecting free cash flow of $320 million to $340 million and adjusted diluted EPS of $0.73 to $0.77, based on approximately 646 million fully diluted adjusted weighted average ordinary shares outstanding.

What Was Disclosed

Clarivate disclosed Q3 and nine-month 2026 financial results, confirmed the October 6, 2026 close of the LS&H segment sale for net cash proceeds of $488.4 million, and updated its full-year and Q4 2026 financial outlook excluding discontinued operations.